3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Terminated
1
Completed
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Thoracic
2
Other solid neoplasm
2
Conditions
Mesothelioma, Malignant
2
Severe combined immunodeficiency with sensitivity to ionizing radiation
1
Pancreatic Neoplasms
1
Interventions
Pemetrexed
15
Cisplatin
13
pembrolizumab
6
Platinum
4
1,2-diaminocyclohexaneplatinum II citrate
4
cediranib
3
Radiotherapy
3
Gemcitabine
3
Carboplatin
3
amatuximab
2
Radiotherapy, Intensity-Modulated
2
Radiation
2
Everolimus
2
Drug Therapy
2
Cyclophosphamide
2
tumor necrosis factor-alpha, CNGRC fusion protein, human
1
tremelimumab
1
sodium thiosulfate
1
sargramostim
1
nintedanib
1
napabucasin
1
methoxyamine
1
liposomal doxorubicin
1
incomplete Freund's adjuvant
1
fresolimumab
1
durvalumab
1
defactinib
1
cixutumumab
1
bintrafusp alfa protein, human
1
bemcentinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Has results
×
Mesothelioma, Malignant
×
amatuximab
×
Clear all
NCT00738582
2022-09-22
Amatuximab
Morphotek
Phase 2
Completed
89 enrolled
12 charts
NCT02357147
2020-03-17
ARTEMIS
Morphotek
Phase 2
Terminated
124 enrolled
10 charts